December 1, 2012, Richmond, VA-Virginia Urology is proud to introduce a powerful new MR solution for targeted biopsy of the prostate. Through our recent adoption of the UroNav fusion biopsy system, we are can offer a truly new biopsy option for many patients with elevated and/or rising PSA levels.
Targeted MR/ultrasound biopsy is poised to become the new standard in prostate care, and Virginia Urology is pleased to be one of the first urology groups in the area to offer this powerful solution to our patients. UroNav fuses pre-biopsy MR images of the prostate with ultrasound-guided biopsy images in real time, for excellent delineation of the prostate and suspicious lesions.
After a patient has undergone a prostate MRI, our radiology partners utilize DynaCAD for Prostate to quickly visualize and evaluate suspicious lesions. Our UroNav fusion biopsy system uses this critical diagnostic information to provide our skilled urologists with a targeted approach to prostate biopsy. The fusion of MR and ultrasound images through UroNav gives our urologists the ability to offer their patients an alternative to remaining in an uncertain state of diagnosis after a prostate exam.
“We are excited to be able to offer our patients the latest technology. This allows us to identify suspicious lesions in the prostate and target them for biopsies. We hope that will decrease the number of total biopsies and repeat biopsies, and increase the detection of significant prostate cancer” explains Eric P. Cote, MD, Urologist, Virginia Urology Cancer Committee.
Other than skin cancer, prostate cancer has become the most common form of cancer in American men and the second-leading cause of cancer death in this population. As 1 man in 6 will be diagnosed with prostate cancer during his lifetime*, Virginia Urology’s introduction of MR/ultrasound fusion biopsy could not have come at a more opportune time.
For more information about Virginia Urology and MR/ultrasound fusion, please call us at 804-330-9105 or visit us on the web at uro.com.
* American Cancer Society (http://www.cancer.org), 2013